Monopar Therapeutics (MNPR) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
MNPR currently has 6.7M outstanding shares. with significant dilution risk as 4.04M authorized shares could dilute existing holders by 60.3%. The company has significantly diluted shareholders by 83.08% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 14, 2026 |
10-Q filing | 6.7M shares outstanding |
6.7M | 4M |
| Sep 24, 2025 |
8-K filing: Monopar Therapeutics Inc. executed an underwritten registered offering of common stock and pre-funded warrants, and simultaneously repurchased shares from a significant stockholder. |
6.1M | 4M |
| Aug 29, 2025 |
S-3 filing: The company is filing an S-3 registration statement to register an indeterminate number of shares of common stock, warrants to purchase common stock, subscription rights to purchase securities, and units comprised of one or more of the other securities for an aggregate initial offering price not to exceed $300,000,000. |
6.1M | 4M |
| Aug 12, 2025 |
10-Q filing | 6.1M shares outstanding |
6.1M | 4M |
| May 13, 2025 |
10-Q filing | 6.1M shares outstanding |
6.1M | 4M |
| Mar 31, 2025 |
10-K filing | 6.1M shares outstanding |
6.1M | 4M |
| Jan 15, 2025 |
S-3 filing: Resale of common stock issuable upon exercise of pre-funded warrants. |
3.5M | 4M |
| Dec 23, 2024 |
8-K filing: Monopar Therapeutics Inc. entered into an Underwriting Agreement to issue and sell 798,655 shares of common stock at $23.79 per share and a Securities Purchase Agreement for pre-funded warrants to purchase 882,761 shares of common stock at $23.789 per warrant. |
3.5M | 3.2M |
| Nov 29, 2024 |
S-3 filing: The filing relates to the resale of up to 705,015 shares of common stock by the selling stockholder. |
3.5M | 3.2M |
| Nov 08, 2024 |
10-Q filing | 3.5M shares outstanding |
3.5M | 2.5M |
| Oct 30, 2024 |
8-K filing: Monopar Therapeutics Inc. entered into a placement agent agreement with Rodman & Renshaw LLC for the offer and sale of up to 1,181,540 shares of common stock at $16.25 per share, which closed on October 30, 2024, resulting in gross proceeds of approximately $19.2 million before deducting fees and expenses. ($19.2M proceeds) |
18M | 2.5M |
| Oct 24, 2024 |
8-K filing: Monopar Therapeutics Inc. executed a License Agreement with Alexion Pharmaceuticals, Inc., issuing 387,329 shares of common stock to Alexion as part of the consideration, representing a 9.9% beneficial ownership interest. |
18M | 2.5M |
| Aug 09, 2024 |
10-Q filing | 17.5M shares outstanding |
18M | 2.5M |
| May 09, 2024 |
10-Q filing | 16.0M shares outstanding |
16M | 2.5M |
| Mar 28, 2024 |
10-K filing | 13.8M shares outstanding |
14M | 2.5M |
| Nov 09, 2023 |
10-Q filing | 14.1M shares outstanding |
14M | 2.5M |
| Aug 10, 2023 |
10-Q filing | 13.4M shares outstanding |
13M | 2.5M |
| May 11, 2023 |
10-Q filing | 12.9M shares outstanding |
13M | 2.5M |
| Mar 23, 2023 |
10-K filing | 12.7M shares outstanding |
13M | 2.5M |
| Dec 21, 2022 |
S-3 filing: The company is filing an S-3 to register shares of common stock for sale from time to time, up to $100,000,000. Shares of our Common Stock having an aggregate offering price up to $6,505,642 in an at-the-market offering that may be made from time to time on Nasdaq through or to the Agent, as sales agent or principal. |
13M | 2.5M |
| Nov 10, 2022 |
10-Q filing | 12.6M shares outstanding |
13M | 0 |
| Aug 11, 2022 |
10-Q filing | 12.6M shares outstanding |
13M | 0 |
| May 12, 2022 |
10-Q filing | 12.6M shares outstanding |
13M | 0 |
| Mar 24, 2022 |
10-K filing | 11.5M shares outstanding |
11M | 0 |
| Nov 12, 2021 |
10-Q filing | 11.5M shares outstanding |
11M | 0 |
| Aug 12, 2021 |
10-Q filing | 12.6M shares outstanding |
13M | 0 |
| May 13, 2021 |
10-Q filing | 12.6M shares outstanding |
13M | 0 |
| Mar 25, 2021 |
10-K filing | 11.5M shares outstanding |
11M | 0 |
| Nov 12, 2020 |
10-Q filing | 11.5M shares outstanding |
11M | 0 |
| Aug 06, 2020 |
10-Q filing | 10.7M shares outstanding |
11M | 0 |
| May 07, 2020 |
10-Q filing | 10.6M shares outstanding |
11M | 0 |
| Mar 27, 2020 |
10-K filing | 10.6M shares outstanding |
11M | 0 |
| Jan 03, 2020 |
S-3 filing: The filing is an S-3 shelf registration statement for common stock. |
N/A | 0 |